Christopher Humphries

Featured in: Favicon

Articles

Macrophage Therapy for Acute Liver Injury (MAIL): a Phase 1 Randomised, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Activity of Allogeneic Alternatively Activated Macrophages in Patients with Paracetamol-induced Acute Liver In…

May 28, 2024 | medrxiv.org | Christopher Humphries |Guruprasad P. Aithal |Julia A. Boyd |Melisande Addison

All authors acknowledge that work for the MAIL Trial and publication of this manuscript is supported by MRC and CSO funding. GA: consulting fees from Clinipace, GSK, Amryth, Pfizer, DNDi, BenevolentAI Bio, PureTech LYT, Merck, Agios, Astra Zeneca, Suzhou MDCE. JCa: advisor to, founding member of, and stock options in Resolution Therapeutics, multiple patents related to delivery of macrophage cell therapy.
‘From harm to hope’: the UK government’s 10-year drug plan to cut crime and save lives - an emergency medicine perspective

Feb 23, 2023 | emj.bmj.com | Christopher Humphries

http://orcid.org/0000-0002-6231-2603Christopher HumphriesEmergency Medicine, Plymouth Hospitals NHS Trust, Plymouth, UKCorrespondence to Dr Christopher Humphries, Emergency Medicine, Plymouth Hospitals NHS Trust, Plymouth, UK; cphumphries{at}doctors.org.uk Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.